alpha-synuclein and Metabolic-Syndrome

alpha-synuclein has been researched along with Metabolic-Syndrome* in 1 studies

Reviews

1 review(s) available for alpha-synuclein and Metabolic-Syndrome

ArticleYear
Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson's Disease.
    ACS chemical neuroscience, 2022, 08-03, Volume: 13, Issue:15

    Parkinson's disease (PD) is a neurodegenerative disorder that gradually develops over time in a progressive manner. The main culprit behind the disease pathology is dopaminergic deficiency in Substantia nigra Pars Compacta (SNpc) due to neuronal degeneration. However, there are other factors that are not only associated with it but also somehow responsible for inception of pathology. Metabolic syndrome is one such risk factor for PD. Metabolic syndrome is a cluster of diseases mainly including diabetes, hypertension, obesity, and hyperlipidemia which pose a risk for developing cardiovascular disorders. All of these disorders have their own pathological pathways that intertwine with PD pathology. This leads to alpha-synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and oxidative stress which are facets in initiating PD pathology. Although few reports are available, this area is underexplored and has contradictory views. Hence, further studies are needed in order to establish a definite relationship between PD and metabolic syndrome. In this review, we aim to elucidate the molecular mechanisms to confirm the association between them and pave the way for potential repurposing of therapies.

    Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; Metabolic Syndrome; Oxidative Stress; Parkinson Disease; Pars Compacta

2022